After Crypto: Are Psychedelics the Next Trend? | Midas Letter RAW ft MYND, CHIP.H, AWKN
Cryptocurrencies have exploded in perceived value in recent years. However, the most famous example Bitcoin (BTC), topping $64,000 in April, has now halved in value. The first chink in the armour came in May after promoter Elon Musk tweeted Tesla would stop using Bitcoin as a form of payment over concerns of the cryptocurrency’s impact on fossil fuels. Then, in early June, Bitcoin fell further amid concerns of its use in the Colonial Pipeline ransomware attack. Now, central banks are entering into the equation, saying they need to step in to serve the public interest and roll out their own versions of cryptos…
After Bitcoin erased its gains for 2021, investors are on the lookout for the next best investment opportunity.
Are psychedelics the next trend?
Magic mushrooms are gaining more investor interest after clinical trials show positive results in mental health patients compared with current pharmaceutical methods.
Several companies are now conducting the proper scientific research identifying the healing effects of psychedelic active ingredients and are opening up a new market with their new medical products.
We have 3 interviews on deck during this show. Two is with psychedelic companies trying to solve the mental health equation.
1.MYND Life Sciences (CNSX:MYND)
MYND is advancing novel technologies through clinical trials with an initial focus on major depressive disorder. In addition, MYND is driving toward the initiation of up to six clinical trials on the efficacy of psilocybin and psilocybin analogs, with plans to initiate the trials by Q4 2021. MYND started trading on the Canadian Stock Exchange on May 26.
Health Logic connects patient’s smartphones, and digital continued care platforms. Their patent-pending lab-on-chip technology provides rapid results and facilitates transferring that data from the diagnostic device to the patient’s smartphone. This data collection better assesses patient risk profiles and provides better patient outcomes. In other words: early detection any time, anywhere, with actionable digital management for chronic kidney disease (CKD).
3. AWAKN Life Sciences (NEO:AWKN)
Viewers of Midas Letter may remember George Scorsis from Liberty Health Sciences or other cannabis ventures. He is now the chair at AWAKN. A company delivering psychedelic therapies for addiction in clinics in the UK and Europe and licencing global partnerships. AWAKN already has strategic partnerships with 2 leading UK universities for exclusive access to data and findings from recent clinical trials. AWKN started trading on June 23 on the NEO stock exchange.
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.